Disappointingly, the results of the JAVELIN 300 trial recently failed to reach its primary endpoint OS in order to consider avelumab as a third-line treatment option for advanced GC/GEJC adenocarcinoma that did not test for PD-L1. This evidence concerns the gene CD274 and gastric cancer.